Paper31056705
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Lee HA and 6 others. Rheumatology (Oxford), 2019. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. Papers, record 31056705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31056705
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hydrocarbons, Brominated | Major topic |
| Organic Anion Transporters | Major topic |
| Organic Cation Transport Proteins | Major topic |
| Uric Acid | Major topic |
| Uricosuric Agents | Major topic |
| Administration, Oral | |
| Adult | |
| Asian People | |
| Double-Blind Method | |
| Gout | |
| Healthy Volunteers | |
| Humans | |
| Hyperuricemia | |
| Male | |
| White People |
Source PubMed
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01953497 | Phase 1 Study of URC102 in Healthy Subjects | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02524678 | Phase 1 Study(Additional) of URC102 in Healthy Subjects | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT07324434 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects | Background | ClinicalTrials.gov | |
| NCT07346027 | Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects | Background | ClinicalTrials.gov |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42542893 | The Dual Role of Uric Acid: Pathological Implications Across Chronic Diseases and Current Approaches to Hyperuricemia Management. | Discoveries (Craiova) | 2026 | https://conductscience.org/library/papers/42542893 | PubMed |
| 41753671 | Serum Uric Acid-Reducing Effect and Intestinal Mucosal Barrier-Repairing Function of Limosilactobacillus reuteri MBHC10138. | Microorganisms | 2026 | https://conductscience.org/library/papers/41753671 | PubMed |
| 41340907 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Oral Doses of ABP-671 in Healthy and Hyperuricemic Subjects. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41340907 | PubMed |
| 41065961 | URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies. | Inflammopharmacology | 2025 | https://conductscience.org/library/papers/41065961 | PubMed |
| 40513003 | Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor. | Clin Transl Sci | 2025 | https://conductscience.org/library/papers/40513003 | PubMed |
| 40420308 | Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study. | Arthritis Res Ther | 2025 | https://conductscience.org/library/papers/40420308 | PubMed |
| 39385411 | From Patents to Progress: Unraveling Gout's Journey Through Clinical Trials and Advancements. | Rev Recent Clin Trials | 2025 | https://conductscience.org/library/papers/39385411 | PubMed |
| 37819612 | Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review. | Drugs | 2023 | https://conductscience.org/library/papers/37819612 | PubMed |
| 36081938 | Review of Urate-Lowering Therapeutics: From the Past to the Future. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36081938 | PubMed |
| 34204277 | Modulation of Urate Transport by Drugs. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34204277 | PubMed |
| 33568990 | The Efficacy and Mechanism of Chinese Herbal Medicines in Lowering Serum Uric Acid Levels: A Systematic Review. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/33568990 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SLC22A12 | 116085 | PubTator's text mining | https://conductscience.org/library/genes/116085 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31056705
GET https://conductscience.org/api/papers/v1/31056705/authors